Skip to main content
SpringerLink
Log in

Pertuzumab not cost effective for HER2-positive MBC

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2014 US dollars

References

  1. Durkee BY, et al. Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. Journal of Clinical Oncology : 8 Sep 2015. Available from: URL: http://dx.doi.org/10.1200/JCO.2015.62.9105.

  2. Bach PB. Walking the Tightrope Between Treatment Efficacy and Price. Journal of Clinical Oncology : 8 Sep 2015. Available from: URL: http://dx.doi.org/10.1200/JCO.2015.63.7397.

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pertuzumab not cost effective for HER2-positive MBC. PharmacoEcon Outcomes News 737, 24 (2015). https://doi.org/10.1007/s40274-015-2470-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-015-2470-6

Search

Navigation